Surge of serum interleukin-2 level in a Japanese patient with cytarabine syndrome

Pediatr Blood Cancer. 2020 Mar;67(3):e28131. doi: 10.1002/pbc.28131. Epub 2019 Dec 18.

Authors

Yasunori Iida¹, Hiroki Yasudo¹, Reiji Fukano¹, Yoshihiro Azuma¹, Takuya Ichimura¹, Shouichi Ohga², Shunji Hasegawa¹

Affiliations

¹ Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
² Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan.

PMID: 31850653
DOI: 10.1002/pbc.28131

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antimetabolites, Antineoplastic / adverse effects*
Cytarabine / adverse effects*
Cytokine Release Syndrome / blood*
Cytokine Release Syndrome / etiology
Female
Histiocytosis, Langerhans-Cell / drug therapy*
Humans
Infant
Interleukin-2 / blood*
Prognosis

Substances

Antimetabolites, Antineoplastic
IL2 protein, human
Interleukin-2
Cytarabine